Medical Care of Adults with Mental Retardation



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Persons with mental retardation are living longer and integrating into their communities. Primary medical care of persons with mental retardation should involve continuity of care, maintenance of comprehensive treatment documentation, routine periodic health screening, and an understanding of the unique medical and behavioral disorders common to this population. Office visits can be successful if physicians familiarize patients with the office and staff, plan for difficult behaviors, and administer mild sedation when appropriate. Some syndromes that cause mental retardation have specific medical and behavioral features. Health issues in these patients include respiratory problems, gastrointestinal disorders, challenging behaviors, and neurologic conditions. Some commonly overlooked health concerns are sexuality, sexually transmitted diseases, and end-of-life decisions.

Approximately 1 percent of the general population has mental retardation.1 The U.S. Surgeon General has identified “glaring” health disparities in the availability of good health care for adults with mental retardation compared with the general population.2 These disparities are caused in part by inadequate compensation and a lack of experience among health care professionals in meeting the needs of this population.2 Increasing numbers of persons with mental retardation are living into adulthood, and primary care physicians are needed to direct the medical support necessary for successful community integration.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Offer routine, periodic health screening to persons with mental retardation.

C

5

Avoid the use of psychotropic medications for new challenging behaviors until an attempt has been made to rule out potential medical and environmental causes (except when harmful to self or others).

C

52

Consider a conservatorship, and document end-of-life issues for adults not mentally capable of making medical decisions.

C

60


A = consistent, good quality patient-oriented evidence; B = inconsistent or limited quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For more information about the SORT evidence rating system, see page 2105 or http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Offer routine, periodic health screening to persons with mental retardation.

C

5

Avoid the use of psychotropic medications for new challenging behaviors until an attempt has been made to rule out potential medical and environmental causes (except when harmful to self or others).

C

52

Consider a conservatorship, and document end-of-life issues for adults not mentally capable of making medical decisions.

C

60


A = consistent, good quality patient-oriented evidence; B = inconsistent or limited quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For more information about the SORT evidence rating system, see page 2105 or http://www.aafp.org/afpsort.xml.

Although persons with developmental disabilities are designated in different ways (e.g., “intellectually disabled”), this article focuses on the subset of patients with mental retardation (Table 13,4).

TABLE 1

Definitions of Developmental Disabilities and Mental Retardation

Developmental disabilities

Severe chronic mental or physical disabilities that manifest before a person reaches 22 years of age, are likely to continue indefinitely, and result in substantial functional limitations in three or more of the following areas: self-care, receptive and expressive language, learning, mobility, self-direction, capacity for independent living, or economic self-sufficiency3

Mental retardation

Identifies a subset of persons who have developmental disabilities with below-average general intellectual functioning (below 65 to 75) as measured through standardized general aptitude evaluation tools, such as the Wechsler Intelligence Scales or Stanford-Binet Intelligence Scales (mild, 50 to 69; moderate, 35 to 49; severe, 20 to 34; profound, less than 20)

Is present before 18 years of age

Accompanies two or more deficits in adaptive behavior used for everyday living (e.g., communication, self-care, home living, social skills, community use, self-direction, health and safety, functional academics, leisure, work) as determined by a structured evaluation tool such as the Vineland Adaptive Behavior Scales.4


Information from references 3 and 4.

TABLE 1   Definitions of Developmental Disabilities and Mental Retardation

View Table

TABLE 1

Definitions of Developmental Disabilities and Mental Retardation

Developmental disabilities

Severe chronic mental or physical disabilities that manifest before a person reaches 22 years of age, are likely to continue indefinitely, and result in substantial functional limitations in three or more of the following areas: self-care, receptive and expressive language, learning, mobility, self-direction, capacity for independent living, or economic self-sufficiency3

Mental retardation

Identifies a subset of persons who have developmental disabilities with below-average general intellectual functioning (below 65 to 75) as measured through standardized general aptitude evaluation tools, such as the Wechsler Intelligence Scales or Stanford-Binet Intelligence Scales (mild, 50 to 69; moderate, 35 to 49; severe, 20 to 34; profound, less than 20)

Is present before 18 years of age

Accompanies two or more deficits in adaptive behavior used for everyday living (e.g., communication, self-care, home living, social skills, community use, self-direction, health and safety, functional academics, leisure, work) as determined by a structured evaluation tool such as the Vineland Adaptive Behavior Scales.4


Information from references 3 and 4.

General Health Care Guidelines

For physician office visits, patients with mental retardation should be accompanied by a person who is familiar with them and the purpose of the visit. Providing caregivers in advance with a referral sheet documenting the information expected for each office visit can be helpful (Figure 1). For patients with destructive or challenging behaviors, physical and emotional trauma can be minimized and the effectiveness of the evaluation enhanced by providing mild sedation (e.g., lorazepam [Ativan], 1 to 8 mg). Additional components of successful primary care office visits are listed in Table 2.

Patient Encounter Form

Figure 1.

Encounter sheet for caregivers of patients with mental retardation to fill out before each physician visit.

View Large

Patient Encounter Form


Figure 1.

Encounter sheet for caregivers of patients with mental retardation to fill out before each physician visit.

Patient Encounter Form


Figure 1.

Encounter sheet for caregivers of patients with mental retardation to fill out before each physician visit.

TABLE 2

Components of a Successful Examination of the Patient with Mental Retardation

Gradually desensitize the patient to the office and staff through short social visits.

Minimize environmental noise (e.g., intercom pages, loud music).

Tell the patient what you are doing as each area is being examined.

Include the patient in the decision-making process as much as possible.

Plan ahead for how to cope with potentially challenging behaviors.

Consider sedating the patient before medical evaluations (e.g., 2 mg of lorazepam [Ativan] two to three hours before visit).

TABLE 2   Components of a Successful Examination of the Patient with Mental Retardation

View Table

TABLE 2

Components of a Successful Examination of the Patient with Mental Retardation

Gradually desensitize the patient to the office and staff through short social visits.

Minimize environmental noise (e.g., intercom pages, loud music).

Tell the patient what you are doing as each area is being examined.

Include the patient in the decision-making process as much as possible.

Plan ahead for how to cope with potentially challenging behaviors.

Consider sedating the patient before medical evaluations (e.g., 2 mg of lorazepam [Ativan] two to three hours before visit).

Patients with mental retardation often have multiple and sometimes complicated medical problems. Maintaining continuity of care and a complete record of all medical interventions is vital. To help keep each patient’s medical records current, caregivers should be reminded to ask consulting physicians to complete and return documentation related to all medical care provided away from the primary care physician’s office. Furthermore, accurate data collection by caregivers is crucial in identifying disorders, monitoring treatment response, and documenting behavioral problems.

Routine periodic health screening should be offered to patients with mental retardation as it is for other adults. The Massachusetts Department of Mental Retardation publishes prevention guidelines more specific to this population (http://www.guidelines.gov/summary/summary.aspx?doc_id=4201).5 Healthy lifestyles and avoidance of high-risk behaviors should be encouraged. Physical activity, often lacking in this population,6 can improve quality of life for many.7 Participation in Special Olympics also should be encouraged, with appropriate screening for event-specific limitations (e.g., atlantoaxial instability in persons with Down syndrome). Genetic evaluation may be helpful in defining specific syndromes.8  This aids physicians in directing genetic family counseling and anticipating associated medical (Table 3)9  and behavioral (Table 4)1018 disorders.

TABLE 3

Medical Phenotypes of Specific Disorders in Persons with Mental Retardation

Disorder Possible medical phenotypic expression

Cerebral palsy

Gastrointestinal: drooling, swallowing disorders

Neuromusculoskeletal: chronic pain (lumbosacral, hip, leg), muscle spasticity, seizures, osteoporosis, scoliosis

Pulmonary: recurrent infections secondary to aspiration

Urinary: incontinence

Cri du chat syndrome

Cardiac: ventricular and atrial septal defects

Orthopedic: scoliosis

Pulmonary: recurrent upper respiratory infection with otitis media

Down syndrome

Cardiac: adults without apparent congenital heart disease may have valvular disease including mitral valve prolapse and aortic regurgitation

Dermatologic: seborrheic dermatitis of scalp and face, eczema of hands and feet, tinea infections including onychomycosis

Endocrine/metabolic: hypothyroidism, diabetes, obesity

ENT: recurring cerumen impactions, hearing loss, upper airway obstruction, obstructive sleep apnea

Gastrointestinal: GERD, often with Schatzki’s ring and Barrett’s esophagus, celiac disease

Neurologic: dementia, seizures

Ophthalmic: strabismus, cataracts, decreased visual acuity

Orthopedic: atlantoaxial instability, patellar subluxation, hip disease, osteoporosis

Neurofibromatosis 1

Cancer: neurofibrosarcoma

Cardiovascular: hypertension

Neurologic: tumors may develop in the brain, on cranial nerves, or on the spinal cord

Orthopedic: enlargement and deformation of bones, scoliosis

Prader-Willi syndrome

Dermatologic: leg edema or ulceration, lesions on head and anterior legs from skin picking

ENT: obstructive sleep apnea

Gastrointestinal: gastroparesis, acute idiopathic gastric dilatation

Metabolic: insulin resistance, hyperlipidemia, hypertension, growth hormone deficiency, water intoxication, obesity

Neurologic: exaggerated responses to standard dosages of anesthetic and sedative agents

Orthopedic: scoliosis, osteoporosis

Rett syndrome

Cardiorespiratory: prolonged QT interval, episodic apnea or hyperpnea

Gastrointestinal: drooling, GERD, swallowing difficulties caused by oropharyngeal and gastroesophageal incoordination, constipation with functional megacolon, gallbladder dysfunction

Neuromusculoskeletal: seizures, gait apraxia and truncal ataxia, scoliosis, osteoporosis

Tuberous sclerosis

Cardiac: congestive heart failure, hypertension

Dermatologic: facial, ungual angiofibromas

Neurologic: seizures, obstructive hydrocephalus

Ophthalmic: retinal hamartomas or phakomas

Orthopedic: cystic defects in the metacarpals, metatarsals, or phalanges; erosions of the tufts of the distal phalanges

Pulmonary: fibrosis, pneumothorax


ENT = ear, nose, and throat; GERD = gastroesophageal reflux disease.

Information from reference 9.

TABLE 3   Medical Phenotypes of Specific Disorders in Persons with Mental Retardation

View Table

TABLE 3

Medical Phenotypes of Specific Disorders in Persons with Mental Retardation

Disorder Possible medical phenotypic expression

Cerebral palsy

Gastrointestinal: drooling, swallowing disorders

Neuromusculoskeletal: chronic pain (lumbosacral, hip, leg), muscle spasticity, seizures, osteoporosis, scoliosis

Pulmonary: recurrent infections secondary to aspiration

Urinary: incontinence

Cri du chat syndrome

Cardiac: ventricular and atrial septal defects

Orthopedic: scoliosis

Pulmonary: recurrent upper respiratory infection with otitis media

Down syndrome

Cardiac: adults without apparent congenital heart disease may have valvular disease including mitral valve prolapse and aortic regurgitation

Dermatologic: seborrheic dermatitis of scalp and face, eczema of hands and feet, tinea infections including onychomycosis

Endocrine/metabolic: hypothyroidism, diabetes, obesity

ENT: recurring cerumen impactions, hearing loss, upper airway obstruction, obstructive sleep apnea

Gastrointestinal: GERD, often with Schatzki’s ring and Barrett’s esophagus, celiac disease

Neurologic: dementia, seizures

Ophthalmic: strabismus, cataracts, decreased visual acuity

Orthopedic: atlantoaxial instability, patellar subluxation, hip disease, osteoporosis

Neurofibromatosis 1

Cancer: neurofibrosarcoma

Cardiovascular: hypertension

Neurologic: tumors may develop in the brain, on cranial nerves, or on the spinal cord

Orthopedic: enlargement and deformation of bones, scoliosis

Prader-Willi syndrome

Dermatologic: leg edema or ulceration, lesions on head and anterior legs from skin picking

ENT: obstructive sleep apnea

Gastrointestinal: gastroparesis, acute idiopathic gastric dilatation

Metabolic: insulin resistance, hyperlipidemia, hypertension, growth hormone deficiency, water intoxication, obesity

Neurologic: exaggerated responses to standard dosages of anesthetic and sedative agents

Orthopedic: scoliosis, osteoporosis

Rett syndrome

Cardiorespiratory: prolonged QT interval, episodic apnea or hyperpnea

Gastrointestinal: drooling, GERD, swallowing difficulties caused by oropharyngeal and gastroesophageal incoordination, constipation with functional megacolon, gallbladder dysfunction

Neuromusculoskeletal: seizures, gait apraxia and truncal ataxia, scoliosis, osteoporosis

Tuberous sclerosis

Cardiac: congestive heart failure, hypertension

Dermatologic: facial, ungual angiofibromas

Neurologic: seizures, obstructive hydrocephalus

Ophthalmic: retinal hamartomas or phakomas

Orthopedic: cystic defects in the metacarpals, metatarsals, or phalanges; erosions of the tufts of the distal phalanges

Pulmonary: fibrosis, pneumothorax


ENT = ear, nose, and throat; GERD = gastroesophageal reflux disease.

Information from reference 9.

TABLE 4

Behavioral Phenotypes of Specific Disorders in Persons with Mental Retardation

Disorder Behavioral phenotype Specific interventions

Angelman’s syndrome10

Absence of speech but with paroxysmal laughter and smiling; fascination with water; sleep disturbance

Requires close supervision when around water; melatonin

Prader-Willi syndrome11,12

Obesity, food-seeking and food-hoarding behaviors; antisocial with temper tantrums; obsessive-compulsive features such as skin picking, ordering impulsivity; labile affect; psychosis; sleep disturbance

Group psychotherapy; SSRIs

Williams syndrome13

Overly friendly and highly sensitive to rejection; impulsivity; incessant chatter; fearful and worrisome; has few friends

Intervention for anxiety

Fetal alcohol syndrome14

ADHD; inappropriate sexual behavior and sexually offending behaviors (e.g., touching, incest); substance abuse; anxiety disorders, depression, mania; sleep disorders; aggression, conduct disorders, oppositional defiant disorders, adjustment disorders; visual-motor/visuospatial coordination deficits; speech/language impairments

Psychosocial intervention; stimulants; SSRIs; atypical antipsychotics; mood stabilizers

Down syndrome15

Depression; obsessional slowness; obsessive-compulsive disorder; autism; dementia after 50 years of age

Psychosocial intervention; SSRIs

Rett syndrome16

Repeated movements, hand stereotypy, facial twitches; social interaction (autistic-relating) problems; mood disturbance, fear, anxiety; insomnia; autistic behaviors

SSRIs, risperidone (Risperdal), melatonin

Fragile X17 syndrome

Hyperarousal, anxiety, ADHD, aggression, autism

SSRIs, stimulants, clonidine (Catapres), atypical antipsychotics, mood stabilizers

Phenylketonuria18

Autism, ADHD, agoraphobia

Maintenance of phenylalanine-free diet


SSRI = selective serotonin reuptake inhibitor; ADHD = attention-deficit/hyperactivity disorder.

Information from references 10 through 18.

TABLE 4   Behavioral Phenotypes of Specific Disorders in Persons with Mental Retardation

View Table

TABLE 4

Behavioral Phenotypes of Specific Disorders in Persons with Mental Retardation

Disorder Behavioral phenotype Specific interventions

Angelman’s syndrome10

Absence of speech but with paroxysmal laughter and smiling; fascination with water; sleep disturbance

Requires close supervision when around water; melatonin

Prader-Willi syndrome11,12

Obesity, food-seeking and food-hoarding behaviors; antisocial with temper tantrums; obsessive-compulsive features such as skin picking, ordering impulsivity; labile affect; psychosis; sleep disturbance

Group psychotherapy; SSRIs

Williams syndrome13

Overly friendly and highly sensitive to rejection; impulsivity; incessant chatter; fearful and worrisome; has few friends

Intervention for anxiety

Fetal alcohol syndrome14

ADHD; inappropriate sexual behavior and sexually offending behaviors (e.g., touching, incest); substance abuse; anxiety disorders, depression, mania; sleep disorders; aggression, conduct disorders, oppositional defiant disorders, adjustment disorders; visual-motor/visuospatial coordination deficits; speech/language impairments

Psychosocial intervention; stimulants; SSRIs; atypical antipsychotics; mood stabilizers

Down syndrome15

Depression; obsessional slowness; obsessive-compulsive disorder; autism; dementia after 50 years of age

Psychosocial intervention; SSRIs

Rett syndrome16

Repeated movements, hand stereotypy, facial twitches; social interaction (autistic-relating) problems; mood disturbance, fear, anxiety; insomnia; autistic behaviors

SSRIs, risperidone (Risperdal), melatonin

Fragile X17 syndrome

Hyperarousal, anxiety, ADHD, aggression, autism

SSRIs, stimulants, clonidine (Catapres), atypical antipsychotics, mood stabilizers

Phenylketonuria18

Autism, ADHD, agoraphobia

Maintenance of phenylalanine-free diet


SSRI = selective serotonin reuptake inhibitor; ADHD = attention-deficit/hyperactivity disorder.

Information from references 10 through 18.

Up to 50 percent of patients coming from institutions may have a history of hepatitis A or B infection.19 Screening and vaccination for hepatitis B should be considered.5

Oral Hygiene

Oral hygiene often is neglected in adults with mental retardation,20 and obtaining access to good dental care can be difficult.21 Periodontal disease is common and can be a source of discomfort, fever, and challenging behaviors, especially in persons with communication difficulties. Hospitalization may be necessary to provide adequate dental care for persons unable to tolerate outpatient settings.22 Physicians should emphasize regular dental evaluations and consider mild sedation for outpatient dental visits.

Skin Care

Patients with decreased mobility or incontinence are at increased risk of skin breakdown. Caregivers should be counseled on appropriate skin care, and physicians should evaluate patients routinely for skin breakdown.

Persons with tracheotomy and percutaneous endoscopic gastrostomy (PEG) sites may have chronic colonization with bacteria such as methicillin-resistant Staphylococcus aureus.23 Communicable disease guidelines for this population address treatment concerns and encourage integration into community or residential programs (http://www.in.gov/isdh/dataandstats/epidem/2004/sep/guidelines.pdf and http://www.cdphe.state.co.us/dc/epidemiology/co_mrsa_schools5_03.pdf).

Respiratory Concerns

Persons with mental retardation, particularly those with Down syndrome, often have obstructive sleep apnea.24 However, many are unable to tolerate continuous positive airway pressure. For persons who require treatment, surgical intervention such as uvulopalatopharyngoplasty or genioglossal advancement may be helpful.25

Gastrointestinal and Feeding Disorders

Many patients with intellectual and physical disabilities develop swallowing difficulties, which can lead to choking, aspiration, malnutrition, and poor hydration.26 Aspiration is particularly common in patients with neuromuscular disorders, is often silent,27 and may lead to significant pulmonary pathology (e.g., aspiration, bronchitis, pneumonia) and even death from respiratory infection.28 Hypoxemia occurring during oral feedings can be identified by monitoring the patient with pulse oximetry.29

Speech pathology consultation with a fluoroscopic swallowing study can document the presence of aspiration and indicate dietary changes or postural changes during swallowing to minimize aspiration. Because of a limited evidence base, the use of a feeding tube to avoid aspiration with oral feeding is controversial30; however, malnutrition may require nutritional supplementation through a PEG tube.31 Patients who experience aspiration from reflux may benefit from fundoplication or placement of a jejunostomy tube.32

A person with poor verbal skills may have difficulty communicating discomfort related to gastroesophageal reflux disease (GERD). Particularly prevalent in persons with Down syndrome, GERD may cause unexplained sore throat, choking, cough, or changes in behavior.33 Esophagogastroduodenoscopy may be better tolerated and require less patient cooperation than radiographic procedures. It also provides more specific information about the degree of inflammation and pathology and allows for intervention (e.g., dilatation of a Schatzki’s ring).

Constipation and fecal impaction are common in persons with mental retardation34 and may lead to unexplained changes in behavior. These conditions may be caused by an innate predisposition, but medical causes or medication side effects should be considered. There is limited evidence for an ideal treatment regimen in this population. Nonetheless, proactively regulating bowel movements may be more helpful than waiting for symptoms of constipation to be reported by caregivers.

Women’s Health Issues

Menstrual discomfort can be a source of agitation and aggression, including self-injurious behavior.35 When medication fails to control dysmenorrhea or there are serious menstrual hygiene problems, surgery may be a reasonable option.36 It should not be assumed that persons with mental retardation are not sexually active; reproduction and sexually transmitted diseases should be considered. Surgical or medical interventions affecting reproductive ability require an awareness of relevant ethical issues and should be completed only after appropriate consideration of applicable local, state, and federal laws.37

Neurologic Disorders

Seizures in persons with mental retardation are likely to be severe, occur often, and be difficult to control38; increase as the degree of psychomotor retardation increases39; and decrease life expectancy by up to 20 years.40 When obtaining information from caregivers about new onset of seizures in patients taking metoclopramide (Reglan) or neuroleptics, physicians must be careful because extra-pyramidal signs and tardive dyskinesia may be mistaken for seizures. Furthermore, physicians should incorporate surveillance for these medication-related movement disorders in patients taking these medications. The Abnormal Involuntary Movement Scale is available online at http://www.atlantapsychiatry.com/forms/AIMS.pdf.

Many persons with mental retardation, especially those with Down syndrome, do not have predictable responses to pain. Therefore, pain is an unreliable indicator for the presence or severity of many disorders,41 resulting in delayed diagnosis and intervention and an increased risk of morbidity and mortality.42 Given the uncertainty of individual pain perception and response, new onset of pain must be evaluated thoroughly.

Musculoskeletal Conditions

Neuromuscular scoliosis is common among persons with mental retardation, especially those with cerebral palsy. Bracing is unlikely to be effective in stabilizing this type of scoliosis. Consultation with an orthopedic subspecialist for significant curvature is important because surgical intervention may be required to limit curve progression, respiratory compromise, and pain.43,44

Contractures can develop in persons who do not have use of their lower extremities. Symptomatic relief can be provided by surgical interventions such as tendon lengthening, tendon release, or osteotomy.

Spasticity is a common source of discomfort.45 Oral muscle relaxants can provide mild improvement46 but often have complications such as sedation.47 Physical therapy, prolonged stretching, splinting, and serial casting can be effective, but some patients may require more invasive interventions such as site-specific botulinum toxin (Botox) injections or use of a baclofen (Lioresal) pump.

Osteoporosis is common, particularly among non–weight-bearing patients48; as many as 50 percent of adults with mental retardation have osteoporosis or osteopenia.49 Conditions associated with an increased risk of osteoporosis include cerebral palsy, Down syndrome, use of antiepileptics, special diets (e.g., ketogenic diet for seizure control), and hypogonadism.50 Aggressive evaluation of traumatic injuries with radiographic studies may be justified even when there are few physical findings. Furthermore, osteoporosis and use of antiepileptics may predispose patients to degenerative disk disease with spinal cord compromise, leading to functional decline.51

Behavioral and Psychiatric Interventions

For persons unable to communicate adequately, a change in behavior may be the first indication of a problem. An unrecognized medical disorder or environmental change should be considered before concluding that a new challenging behavior, or an exacerbation of a previous behavior, is caused by an underlying psychiatric disorder (Table 5).52 Given the relationship between mental retardation and family violence and abuse,53 family dynamics also should be evaluated carefully when challenging behaviors are most prevalent in the home.

TABLE 5

Triggers for Challenging Behavior in Persons with Mental Retardation

Type of stressor Examples

Transitional phase

Change of teacher or residence; adolescence; retirement of patient

Interpersonal loss or rejection

Loss of parent, job, romantic partner

Environmental

Stress at group home or day program

Family, social support problems

Neglect from family, friends, caregivers; abuse

Medical or psychiatric illness

Tooth pain; depression

Anger, frustration

Being teased; inability to complete tasks


Information from reference 52.

TABLE 5   Triggers for Challenging Behavior in Persons with Mental Retardation

View Table

TABLE 5

Triggers for Challenging Behavior in Persons with Mental Retardation

Type of stressor Examples

Transitional phase

Change of teacher or residence; adolescence; retirement of patient

Interpersonal loss or rejection

Loss of parent, job, romantic partner

Environmental

Stress at group home or day program

Family, social support problems

Neglect from family, friends, caregivers; abuse

Medical or psychiatric illness

Tooth pain; depression

Anger, frustration

Being teased; inability to complete tasks


Information from reference 52.

Neuropsychiatric disorders such as obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, and mood disorders can occur in persons with mental retardation and, when left untreated, may lead to more challenging behaviors. Although some etiologies of mental retardation may have associated behavioral phenotypes (Table 4),1018 most challenging behaviors are caused by the same neuropsychiatric disorders that affect the general population54 and respond to the same treatments. One notable exception is benzodiazepine therapy, which can precipitate paradoxical reactions of increased irritability and aggression in 10 to 15 percent of patients with mental retardation.55

Once pharmacologic or behavioral intervention is deemed appropriate and informed consent has been obtained, the goal is to minimize physical and emotional trauma to the patient and caregivers while maximizing community integration. Counseling and psychotherapy should be considered for persons with mild to moderate mental retardation.56 Except for short-term intervention in patients determined to be potentially harmful to themselves or others, medications should not be used to restrict behaviors. Treatment should be directed at an underlying medical condition, environmental change, or psychiatric disorder.

Because many persons with mental retardation have greater access to their community than others, they should be educated about the inappropriate use of illicit drugs and alcohol.57  It also is important to provide patients and caregivers with information on relationship development, sexuality, sexual abuse, pregnancy prevention, and protection from sexually transmitted diseases (Table 6).58,59  Sexually offending behavior is concerning, but a number of interventions are available (Table 7).52

TABLE 6

Topics to Address Regarding Relationships, Sexuality, and Protection from Harm in Persons with Mental Retardation

Protection from harm

Alcohol and drug use

Physical, emotional, and sexual abuse

Pregnancy

Sexually transmitted diseases

Relationship development

Respecting the boundaries of other persons

Setting boundaries

Sexuality

Appropriate and inappropriate behaviors

Appropriate and inappropriate dress

Appropriate and inappropriate places for behavior (e.g., masturbation)

TABLE 6   Topics to Address Regarding Relationships, Sexuality, and Protection from Harm in Persons with Mental Retardation

View Table

TABLE 6

Topics to Address Regarding Relationships, Sexuality, and Protection from Harm in Persons with Mental Retardation

Protection from harm

Alcohol and drug use

Physical, emotional, and sexual abuse

Pregnancy

Sexually transmitted diseases

Relationship development

Respecting the boundaries of other persons

Setting boundaries

Sexuality

Appropriate and inappropriate behaviors

Appropriate and inappropriate dress

Appropriate and inappropriate places for behavior (e.g., masturbation)

TABLE 7

Challenging Behaviors in Patients with Mental Retardation

Challenging/target behavior Interventions

Sexually offending behavior (e.g., inappropriate touch, public masturbation, hypersexuality, sexual abuse)

Remove prejudice toward healthy, nonoffensive sexual expression; behavioral therapy; psychotropic therapy (identify and treat any comorbid psychiatric disorders; SSRIs, cimetidine [Tagamet], spironolactone [Aldactone], risperidone [Risperdal], medroxyprogesterone [Provera], leuprolide [Lupron])

Self-injuring behavior (e.g., skin picking, head banging, biting)

Risperidone, SSRIs, valproic acid (Depakene), naltrexone (ReVia)

Stereotypy behavior (e.g., repetitive, nonpurposeful movement in persons with pervasive [autistic] spectrum disorders; rocking; hand flapping)

SSRIs, risperidone (2 to 4 mg twice a day), clonidine (Catapres)

Aggression or destruction

Risperidone, valproic acid, clonidine, propranolol (Inderal), buspirone (BuSpar)

Cyclic—consider bipolar disorder and migraine headache syndrome

Poor impulse control disorder—sudden, unexplained aggression that resolves as quickly as it develops

Temporal lobe seizure—sudden, unexplained aggression that resolves as quickly as it develops; associated with a change in sensorium before, during, or after behavior outbursts

Sleep disturbance (may be a symptom of a mood disorder)

Trazodone (Desyrel), zolpidem (Ambien), diphenhydramine (Benadryl), melatonin

Hyperactivity (e.g., autism, ADHD, akathisia if using neuroleptic drugs, side effect of phenobarbital)

Methylphenidate (Ritalin), clonidine, valproic acid, risperidone

Attention deficit (e.g., ADHD, autism)

Methylphenidate, clonidine, bupropion (Wellbutrin)

Repetitive behavior patterns (e.g., becomes “stuck” in an activity, such as hand washing)

SSRIs, risperidone

Obsessive-compulsive disorder—appears stuck in an activity; when redirected, goes back to previous activity and becomes stuck again

Autism—becomes stuck in an activity; when redirected, goes to new activity and may become stuck in that

Miscellaneous—talking aloud to themselves

Not pathologic, intervention not warranted


SSRI = selective serotonin reuptake inhibitors; ADHD = attention-deficit/hyperactivity disorder.

Information from reference 52.

TABLE 7   Challenging Behaviors in Patients with Mental Retardation

View Table

TABLE 7

Challenging Behaviors in Patients with Mental Retardation

Challenging/target behavior Interventions

Sexually offending behavior (e.g., inappropriate touch, public masturbation, hypersexuality, sexual abuse)

Remove prejudice toward healthy, nonoffensive sexual expression; behavioral therapy; psychotropic therapy (identify and treat any comorbid psychiatric disorders; SSRIs, cimetidine [Tagamet], spironolactone [Aldactone], risperidone [Risperdal], medroxyprogesterone [Provera], leuprolide [Lupron])

Self-injuring behavior (e.g., skin picking, head banging, biting)

Risperidone, SSRIs, valproic acid (Depakene), naltrexone (ReVia)

Stereotypy behavior (e.g., repetitive, nonpurposeful movement in persons with pervasive [autistic] spectrum disorders; rocking; hand flapping)

SSRIs, risperidone (2 to 4 mg twice a day), clonidine (Catapres)

Aggression or destruction

Risperidone, valproic acid, clonidine, propranolol (Inderal), buspirone (BuSpar)

Cyclic—consider bipolar disorder and migraine headache syndrome

Poor impulse control disorder—sudden, unexplained aggression that resolves as quickly as it develops

Temporal lobe seizure—sudden, unexplained aggression that resolves as quickly as it develops; associated with a change in sensorium before, during, or after behavior outbursts

Sleep disturbance (may be a symptom of a mood disorder)

Trazodone (Desyrel), zolpidem (Ambien), diphenhydramine (Benadryl), melatonin

Hyperactivity (e.g., autism, ADHD, akathisia if using neuroleptic drugs, side effect of phenobarbital)

Methylphenidate (Ritalin), clonidine, valproic acid, risperidone

Attention deficit (e.g., ADHD, autism)

Methylphenidate, clonidine, bupropion (Wellbutrin)

Repetitive behavior patterns (e.g., becomes “stuck” in an activity, such as hand washing)

SSRIs, risperidone

Obsessive-compulsive disorder—appears stuck in an activity; when redirected, goes back to previous activity and becomes stuck again

Autism—becomes stuck in an activity; when redirected, goes to new activity and may become stuck in that

Miscellaneous—talking aloud to themselves

Not pathologic, intervention not warranted


SSRI = selective serotonin reuptake inhibitors; ADHD = attention-deficit/hyperactivity disorder.

Information from reference 52.

Legal and End-of-Life Issues

Informed consent and capacity for medical decision making can be difficult to assess. It should not be assumed that all adults with mental retardation are unable to make medical decisions. If there are questions about this issue, physicians should consider a formal competency evaluation. Furthermore, families of adults with mental retardation often fear that they will outlive a caring support system; thus, end-of-life concerns are best discussed before a time of crisis develops. Specific end-of-life requests and preferences should be documented. These include religious ceremonies and wishes for final disposition of the body. Although parents have the authority to make medical decisions for their minor children, adult patients with mental retardation who lack adequate medical decision-making capacity should have a conservator appointed to act in their best interest.60 Ideally, this would be a parent or other knowledgeable family member. Although conservators do not have the power to make a living will, individual and family preferences about treatment objectives and parameters for resuscitation efforts can be documented to help guide surrogate decision makers in their absence.

The Authors

CHRISTOPHER D. PRATER, M.D., is assistant clinical professor in the Department of Family Medicine at the University of Tennessee College of Medicine, Chattanooga Unit. He also serves as medical director for the Orange Grove Center, a community-based health care center in Chattanooga serving 500 developmentally delayed children and adults. Dr. Prater received his medical degree from the University of Tennessee College of Medicine, Memphis, and completed a family practice residency at the University of Tennessee in Knoxville.

ROBERT G. ZYLSTRA, ED.D., L.C.S.W., is assistant professor and director of behavioral science in the Department of Family Medicine at the University of Tennessee College of Medicine, Chattanooga Unit. Dr. Zylstra earned his master’s degree in social work from the University of Michigan, Ann Arbor, and his doctorate in educational psychology from the University of Memphis.

Address correspondence to Robert G. Zylstra, Ed.D., L.C.S.W., University of Tennessee College of Medicine, Dept. of Family Medicine, 1100 E. 3rd St., Chattanooga, TN 37403 (e-mail Dr. Zylstra at: robert.zylstra@erlanger.org or Dr. Prater at: cprater@orangegrove.org). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Fujiura GT. Continuum of intellectual disability: demographic evidence for the “forgotten generation.”. Ment Retard. 2003;41:420–9.

2. National Institute of Child Health and Human Development. Closing the gap: a national blueprint for improving the health of persons with mental retardation. Report of the Surgeon General’s Conference on Health Disparities and Mental Retardation. Washington, D.C.: National Institutes of Health, 2001. Accessed September 16, 2005, at:http://www.nichd.nih.gov/publications/pubs/closingthegap/index.htm.

3. Developmental Disabilities Assistance and Bill of Rights Act of 2000. (114 STAT. 1684, PUBLIC LAW 106–402—OCT. 30, 2000). Accessed February 2, 2006, at:http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=106_cong_public_laws&docid=f:publ402.106.pdf.

4. Individuals with Disabilities Education Act. (Public Law 101–476) Mental retardation: definition, classification, and systems of supports. 9th ed. Washington, D.C.: American Association on Mental Retardation, 1992. Accessed February 2, 2006, at:http://thomas.loc.gov/cgi-bin/bdquery/z?d101:SN01824:@@@D&summ2=m&|TOM:/bss/d101query.html|.

5. Massachusetts Department of Mental Retardation, University of Massachusetts Medical School’s Center for Developmental Disabilities Evaluation and Research. Preventive health recommendations for adults with mental retardation. Boston, Mass.: Massachusetts Department of Mental Retardation, 2003. Accessed September 16, 2005, at:http://www.guidelines.gov/summary/summary.aspx?doc_id=4201.

6. Draheim CC, Williams DP, McCubbin JA. Prevalence of physical inactivity and recommended physical activity in community-based adults with mental retardation. Ment Retard. 2002;40:436–44.

7. Heller T, Hsieh K, Rimmer JH. Attitudinal and psychosocial outcomes of a fitness and health education program on adults with Down syndrome. Am J Ment Retard. 2004;109:175–85.

8. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472–86.

9. Jones KL, Smith DW. Smith’s Recognizable Patterns of Human Malformation. 5th ed. Philadelphia, Pa.: Saunders, 1997.

10. Aquino NH, Bastos E, Fonseca LC, Llerena JC Jr. Angelman syndrome methylation screening of 15q11-q13 in institutionalized individuals with severe mental retardation. Genet Test. 2002;6:129–31.

11. Dykens EM. Maladaptive and compulsive behavior in Prader-Willi syndrome: new insights from older adults. Am J Ment Retard. 2004;109:142–53.

12. Dykens E, Shah B. Psychiatric disorders in Prader-Willi syndrome: epidemiology and management. CNS Drugs. 2003;17:167–78.

13. Dykens EM. Intervention issues in persons with Williams syndrome. Ment Health Aspects Dev Disabil. 2001;4:130–7.

14. Steinhausen HC, Willms J, Metzke CW, Spohr HL. Behavioural phenotype in foetal alcohol syndrome and foetal alcohol effects. Dev Med Child Neurol. 2003;45:179–82.

15. Pary RJ. Behavioral and psychiatric disorders in children and adolescents with Down syndrome. Ment Health Aspects Dev Disabil. 2004;7:69–76.

16. Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Towards a behavioral phenotype for Rett syndrome. Am J Ment Retard. 2003;108:1–12.

17. Maes B, Fryns JP, Ghesquiere P, Borghgraef M. Phenotypic checklist to screen for fragile X syndrome in people with mental retardation. Ment Retard. 2000;38:207–15.

18. Levitas AS. Phenylketonuria (PKU) and the hyperphenylalaninemias: III psychiatric and behavioral aspects. Ment Health Aspects Dev Disabil. 1999;2:133–40.

19. Woodruff BA, Vazquez E. Prevalence of hepatitis virus infections in an institution for persons with developmental disabilities. Am J Ment Retard. 2002;107:278–92.

20. Lange B, Cook C, Dunning D, Froeschle ML, Kent D. Improving the oral hygiene of institutionalized mentally retarded clients. J Dent Hyg. 2000;74:205–9.

21. Waldman HB, Perlman SP. Providing dental services for people with disabilities: why is it so difficult?. Ment Retard. 2002;40:330–3.

22. Hulland S, Sigal MJ. Hospital-based dental care for persons with disabilities: a study of patient selection criteria. Spec Care Dentist. 2000;20:131–8.

23. Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49:270–6.

24. Mitchell RB, Call E, Kelly J. Ear, nose and throat disorders in children with Down syndrome. Laryngoscope. 2003;113:259–63.

25. Lafaivre JF, Cohen SR, Burstein FD, Simms C, Scott PH, Montgomery GL, et al. Down syndrome: identification and surgical management of obstructive sleep apnea. Plast Reconstr Surg. 1997;99:629–37.

26. Kennedy M, McCombie L, Dawes P, McConnell KN, Dunnigan MG. Nutritional support for patients with intellectual disability and nutrition/dysphagia disorders in community care. J Intellect Disabil Res. 1997;41(pt 5):430–6.

27. Rogers B, Stratton P, Msall M, Andres M, Champlain MK, Koerner P, et al. Long-term morbidity and management strategies of tracheal aspiration in adults with severe developmental disabilities. Am J Ment Retard. 1994;98:490–8.

28. Chaney RH, Eyman RK. Patterns in mortality over 60 years among persons with mental retardation in a residential facility. Ment Retard. 2000;38:289–93.

29. Rogers B, Msall M, Shucard D. Hypoxemia during oral feedings in adults with dysphagia and severe neurological disabilities. Dysphagia. 1993;8:43–8.

30. Sleigh G, Brocklehurst P. Gastrostomy feeding in cerebral palsy: a systematic review. Arch Dis Child. 2004;89:534–9.

31. Angus F, Burakoff R. The percutaneous endoscopic gastrostomy tube: medical and ethical issues in placement. Am J Gastroenterol. 2003;98:272–7.

32. Taylor HM. Pneumonia frequencies with different enteral tube feeding access sites. Am J Ment Retard. 2002;107:175–80.

33. Bohmer CJ, Klinkenberg-Knol EC, Niezende Boer MC, Meuwissen SG. Gastroesophageal reflux disease in intellectually disabled individuals: how often, how serious, how manageable?. Am J Gastroenterol. 2000;95:1868–72.

34. Bohmer CJ, Taminiau JA, Klinkenberg-Knol EC, Meuwissen SG. The prevalence of constipation in institutionalized people with intellectual disability. J Intellect Disabil Res. 2001;45(pt 3):212–8.

35. Carr EG, Smith CE, Giacin TA, Whelan BM, Pancari J. Menstrual discomfort as a biological setting event for severe problem behavior: assessment and intervention. Am J Ment Retard. 2003;108:117–33.

36. Paransky OI, Zurawin RK. Management of menstrual problems and contraception in adolescents with mental retardation: a medical, legal, and ethical review with new suggested guidelines. J Pediatr Adolesc Gynecol. 2003;16:223–35.

37. American College of Obstetrics and Gynecology. Sterilization of women, including those with mental disabilities. Accessed September 16, 2005, at:http://www.acog.org/from_home/publications/ethics/ethics056.pdf.

38. Vinning EP, Freeman JM. Epilepsy and developmental disabilities. In: Capute AJ, Accardo PJ, eds. Developmental Disabilities in Infancy and Childhood. 2nd ed. Baltimore, Md.: P.H. Brookes, 1996:511–20.

39. Hayashi Y, Hanada K, Horiuchi I, Morooka M, Yamatogi Y. Epilepsy in patients with severe motor and intellectual disabilities: a long-term follow-up. No To Hattatsu. 2001;33:416–20.

40. Morgan CL, Baxter H, Kerr MP. Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability. Am J Ment Retard. 2003;108:293–300.

41. Hennequin M, Morin C, Feine JS. Pain expression and stimulus localisation in individuals with Down’s syndrome [Published correction appears in Lancet 2001;357:890]. Lancet. 2000;356:1882–7.

42. Biersdorff KK. Incidence of significantly altered pain experience among individuals with developmental disabilities. Am J Ment Retard. 1994;98:619–31.

43. Berven S, Bradford DS. Neuromuscular scoliosis: causes of deformity and principles for evaluation and management. Semin Neurol. 2002;22:167–78.

44. Thacker M, Hui JH, Wong HK, Chatterjee A, Lee EH. Spinal fusion and instrumentation for paediatric neuromuscular scoliosis: retrospective review. J Orthop Surg (Hong Kong). 2002;10:144–51.

45. Pfister AA, Roberts AG, Taylor HM, Noel-Spaudling S, Damian MM, Charles PD. Spasticity in adults living in a developmental center. Arch Phys Med Rehabil. 2003;84:1808–12.

46. Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol. 1996;11:77–83.

47. Meythaler JM, Clayton W, Davis LK, Guin-Renfroe S, Brunner RC. Orally delivered baclofen to control spastic hypertonia in acquired brain injury. J Head Trauma Rehabil. 2004;19:101–8.

48. Henderson RC, Lark RK, Gurka MJ, Worley G, Fung EB, Conaway M, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics. 2002;110(1 pt 1):e5.

49. Tyler CV Jr, Snyder CW, Zyzanski S. Screening for osteoporosis in community-dwelling adults with mental retardation [Published correction appears in Ment Retard 2001;39:39]. Ment Retard. 2000;38:316–21.

50. Center J, Beange H, McElduff A. People with mental retardation have an increased prevalence of osteoporosis: a population study. Am J Ment Retard. 1998;103:19–28.

51. Curtis R, Freitag P, LaGuardia JJ, Thornton S, Vicari S, Markwell S. Spinal cord compromise: an important but underdiagnosed condition in people with mental retardation. Public Health Rep. 2004;119:396–400.

52. Expert Consensus Guideline Series: treatment of psychiatric and behavioral problems in mental retardation.. Am J Ment Retard. 2000;105:159–226.

53. Strickler HL. Interaction between family violence and mental retardation. Ment Retard. 2001;39:461–71.

54. Rojahn J, Matson JL, Naglieri JA, Mayville E. Relationships between psychiatric conditions and behavior problems among adults with mental retardation. Am J Ment Retard. 2004;109:21–33.

55. Kalachnik JE, Hanzel TE, Sevenich R, Harder SR. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. Am J Ment Retard. 2002;107:376–410.

56. Prout HT, Nowak-Drabik KM. Psychotherapy with persons who have mental retardation: an evaluation of effectiveness. Am J Ment Retard. 2003;108:82–93.

57. Cocco KM, Harper DC. Substance use in people with mental retardation: assessing potential problem areas. Ment Health Aspects Dev Disabil. 2002;5:101–8.

58. Elkins TE, Kope S, Ghaziuddin M, Sorg C, Quint E. Integration of a sexuality counseling service into a reproductive health program for persons with mental retardation. J Pediatr Adolesc Gynecol. 1997;10:24–7.

59. American Academy of Pediatrics. Sexuality education of children and adolescents with developmental disabilities. Pediatrics. 1996;97:275–8.

60. American Association on Mental Retardation. AAMR position statements. Accessed September 16, 2005, at:http://www.aamr.org/Policies/position_statements.shtml.


Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article